Research location
Busan
South Korea
Research activity in Busan
South KoreaCureCurrent currently publishes aggregate city-level research activity for this location: 458 trials and 686 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Busan
458 linked trials · page 2 of 10Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 · 2025-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)NCT06710132 · 2025-01-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)NCT06687369 · 2024-12-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in KoreaNCT07018544 · 2024-11-19 · 1 site observation
ENROLLING_BY_INVITATION
Cryobiopsy Vs. Forceps Biopsy for Peripheral Pulmonary LesionsNCT06752395 · 2024-11-01 · 1 site observation
ENROLLING_BY_INVITATION
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)NCT06653153 · 2024-10-24 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Filgotinib in Korean Participants With Rheumatoid ArthritisNCT06625242 · 2024-10-22 · 1 site observation
COMPLETED
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)NCT06430866 · 2024-09-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease PatientsNCT06329141 · 2024-07-22 · 1 site observation
COMPLETED
Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung CancerNCT06301295 · 2024-05-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaNCT06372496 · 2024-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.NCT06268873 · 2024-03-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based ChemotherapyNCT06267001 · 2024-03-21 · 1 site observation
TERMINATED
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyNCT06268613 · 2024-01-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Feasibility of Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Lung CancerNCT06141005 · 2023-11-30 · 1 site observation
COMPLETED
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)NCT06122961 · 2023-11-23 · 1 site observation
COMPLETED
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT06034743 · 2023-11-22 · 1 site observation
COMPLETED
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 · 2023-11-20 · 1 site observation
COMPLETED
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 · 2023-11-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After ChemotherapyNCT05949333 · 2023-11-07 · 1 site observation
UNKNOWN
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisNCT06025578 · 2023-10-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionNCT06041529 · 2023-10-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Kimchi Intake on Body Fat in Overweight SubjectsNCT05898802 · 2023-07-21 · 1 site observation
COMPLETED
A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor MutationsNCT05801029 · 2023-07-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)NCT05607550 · 2023-06-01 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and InflammationNCT05636176 · 2023-05-08 · 1 site observation
TERMINATED
A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)NCT05816252 · 2023-04-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung CancerNCT05652868 · 2023-03-23 · 1 site observation
TERMINATED
A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung CancerNCT05775289 · 2023-03-15 · 1 site observation
COMPLETED
A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)NCT05526755 · 2023-03-06 · 2 site observations
ACTIVE_NOT_RECRUITING
Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With AlbuminuriaNCT05718375 · 2023-02-14 · 1 site observation
COMPLETED
Impact of Lazertinib Dose Modification on Effectiveness and SafetyNCT05716672 · 2023-02-01 · 5 site observations
UNKNOWN
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.NCT05763121 · 2023-01-30 · 1 site observation
TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic AsthmaNCT05748600 · 2023-01-30 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic AlterationsNCT05687266 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant TherapyNCT05550532 · 2022-12-06 · 1 site observation
COMPLETED
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)NCT05629585 · 2022-11-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityNCT05556512 · 2022-10-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)NCT05508789 · 2022-10-10 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast CancerNCT05514054 · 2022-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)NCT05518149 · 2022-09-22 · 1 site observation
TERMINATED
Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High CholesterolNCT07564726 · 2022-08-05 · 2 site observations
COMPLETED
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart FailureNCT05236673 · 2022-07-28 · 4 site observations
COMPLETED
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation TherapyNCT05338619 · 2022-06-30 · 1 site observation
UNKNOWN
Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR MutationNCT06247280 · 2022-06-24 · 5 site observations
ACTIVE_NOT_RECRUITING
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential HypertensionNCT06282549 · 2022-06-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)NCT05374512 · 2022-05-16 · 1 site observation
ACTIVE_NOT_RECRUITING
A 24-week Prospective, Open-label, Multicenter, Single-arm rPMS Study in Real-world Setting for Atectura®NCT05217810 · 2022-05-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A 24-week rPMS Study in Real-world Setting for EnerzairNCT05274425 · 2022-05-09 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)NCT05256134 · 2022-04-19 · 1 site observation
TERMINATED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.